Sat. Jul 20th, 2024 online news,Mumbai,17th June 2024:Alembic Pharmaceuticals Limited today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Icatibant Injection, 30 mg/3 mL (10 mg/mL) Single-Dose Prefilled Syringe.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Firazyr Injection, 30 mg/3 mL (10 mg/mL), of Takeda Pharmaceuticals U.S.A., Inc.

Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. This is the first peptide product approval from the USFDA received by the Company.

Icatibant Injection has an estimated market size of US$ 112 million for twelve months ending Mar 2024 according to IQVIA.

Alembic has a cumulative total of 205 ANDA approvals (177 final approvals and 28 tentative approvals) from USFDA.

Also read : Hyderabad’s popular neighborhood stores now available on PhonePe’s Pincode App

ఇది కూడా చదవండి : హైదరాబాద్ అంతటా ఈద్-ఉల్-అదాను ఘనంగా వేడుకలు

ఇది కూడా చదవండి : బెంగాల్‌లో గూడ్స్ రైలును కాంచన్‌జుంగా ఎక్స్‌ప్రెస్ ఢీకొనడంతో ఐదుగురు మృతి, పలువురు గాయాలు…

ఇది కూడా చదవండి : ఫాదర్స్ డే 2024 ప్రత్యేక సందేశాలు, కోట్స్..